🔗 Share this article

An underground economy for unlicensed slimming medications is being driven by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Experimental Treatment Gaining Traction Online

Retatrutide, which remains in clinical trials, is being advertised by online personalities for its supposed fat-burning effects. Followers are urged to contact these accounts directly for source information, while also obtaining discount codes.

Active Commerce on Social Networks

Additionally, a robust market exists on Telegram, where groups with thousands of participants share “before and after” photos, administration instructions and assertions of next-day UK delivery. Sellers promote the substance there before directing buyers to other platforms for transactions.

Learning About The Experimental Drug

Retatrutide is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could help individuals lose up to a quarter of their total weight. Nicknamed the “triple G”, the drug is being hailed digitally as the next Ozempic.

Healthcare Professionals Express Worries

However, doctors and chemists have warned that the sale of what remains an unlicensed medication in the United Kingdom is a cause for concern and could result in individuals injecting substances of unknown origin.

Several professionals said the demand for the experimental drug could be connected to the rising price of licensed weight loss products such as Mounjaro.

Regulatory Status and Enforcement

Selling retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved drug that cannot be promoted or distributed for human use under the Human Medicines Regulations 2012.

Several content creators attempt to circumvent the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but promotion and supply can still violate medicines, marketing, and consumer laws, risking fines, legal action or prison.

Platform Reaction and Content Removal

Based on the social media company, the service has removed violative material and prohibited related keywords and query recommendations. The company said it was dedicated to keeping the platform safe and investing in enhancing enforcement strategies.

Online Trading Operations

Investigations also found groups with up to nine thousand participants marketing the experimental drug using the platform's integrated search feature, which operates like a online catalog. Entering “retatrutide” immediately displays groups with numerous of users, populated with images of weight loss, glowing reviews and detailed instructions for preparing or administering at residence.

After minutes of joining one community, a seller posted WhatsApp details, where the majority of transactions take place. The vendor provided an instruction manual and guaranteed shipping within 48 hours. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a alleged laboratory certificate. Not one asked about weight, medical conditions or past usage.

Item Details and Pricing

Inside these communities, posts display black plastic packages with Royal Mail labels, claiming to contain new batches. One message read: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at home with purified liquid, or pre-filled pens typically priced at £160 for 20 milligrams. When asked how much time a pen should be used, sellers give conflicting responses ranging from a few weeks to “depends on your body”.

Service Oversight and Safety Actions

A representative for Telegram said it actively monitored dangerous material on its service including material that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are injecting substances they cannot confirm. Although the research behind this drug is valid, these online products may not contain what they claim,” stated Jason Murphy, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the surge in interest to current cost increases for approved weight-loss drugs such as Mounjaro. “With prices increasing, patients are using social media. But counterfeit injections are highly risky. You cannot know what’s inside or whether the environment they were produced in was clean,” she said.

Her staff has already encountered patients injured by self-injection from unconfirmed suppliers. “We understand the frustration, but purchasing from Telegram or WhatsApp is taking chances with your well-being,” said Wyllie. “These materials could be contaminated or improperly measured.”

Producer Statement

A spokesperson from the pharmaceutical company said the substance was in third stage clinical trials and had not been evaluated or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they said, noting that any item “misleadingly claiming itself as a company experimental product not yet approved … may expose users to potentially significant medical dangers”.